tirzepatide surpass cvot SURPASS-CVOT trial: For patients with high-risk type 2 diabetes, the effect of tirzepatide, a dual agonist of the GLP-1 and glucose-dependent insulinotropic polypeptide receptors, on cardiovascular outcomes is uncertain. Research is summarized Diabetes Distilled: SURPASS-CVOT – Tirzepatide

Description

Investigated for metabolic & weight research

Discover how weight loss, diets and medication can work together to keep cholesterol levels in check.

The Tirzepatide Weight Loss Program is a clinician-guided telehealth program built around compounded tirzepatide, a dual-action medication that works on two metabolic pathways (GIP and GLP-1) to reduce appetite, quiet food noise, and support blood sugar balance